Global Premenstrual Syndrome Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Type;

Analgesics, Antidepressants, Oral Contraceptives & Ovarian Suppression Agents and Others.

By Type;

Prescription and OTC.

By Distribution Channel;

Hospitals Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn134735631 Published Date: March, 2025 Updated Date: April, 2025

Introduction

Global Premenstrual Syndrome Treatment Market (USD Million), 2021 - 2031

In the year 2024, the Global Premenstrual Syndrome Treatment Market was valued at USD 1,394.84 million. The size of this market is expected to increase to USD 1,715.48 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.0%.

Premenstrual syndrome (PMS) is a common condition affecting menstruating individuals, characterized by a range of physical and emotional symptoms occurring before menstruation. These symptoms, which can include mood swings, fatigue, bloating, and irritability, can significantly impact quality of life for those affected. As awareness and understanding of PMS have grown globally, there has been a parallel increase in demand for effective treatments to alleviate its symptoms.

In recent years, the global market for premenstrual syndrome treatment has witnessed significant expansion, driven by several factors. One key factor is the rising prevalence of PMS worldwide, attributed to various lifestyle factors, hormonal imbalances, and stress. Additionally, increasing awareness about women's health issues and the destigmatization of discussing menstruation-related concerns have led more individuals to seek medical intervention for managing PMS symptoms.

The market for PMS treatment encompasses a wide range of therapeutic options, including medications, lifestyle modifications, and complementary therapies. Pharmaceutical companies are actively engaged in research and development efforts to introduce novel drug formulations specifically targeting PMS symptoms, aiming for improved efficacy and reduced side effects. Moreover, technological advancements and the advent of telemedicine have facilitated better access to healthcare services, enabling individuals to consult healthcare professionals and access treatment options more conveniently.

The global premenstrual syndrome treatment market is poised for further growth, driven by ongoing research initiatives, increasing healthcare expenditure, and a growing focus on women's health. However, challenges such as the heterogeneity of PMS symptoms and the need for personalized treatment approaches remain significant. Nonetheless, with continued innovation and collaborative efforts across the healthcare sector, there is optimism for the development of more effective and accessible treatments to improve the lives of individuals affected by PMS.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Type
    2. Market Snapshot, By Type
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Premenstrual Syndrome Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growing awareness of PMS
        2. Advances in treatment options
        3. Increasing female population
        4. Rising healthcare expenditure
        5. Demand for symptom relief
      2. Restraints
        1. Side effects of medication
        2. Cultural taboos around PMS
        3. Lack of effective diagnosis
        4. Limited access to healthcare
        5. Economic constraints
      3. Opportunities
        1. Development of novel therapies
        2. Expansion of market reach
        3. Technological innovations in treatment
        4. Focus on holistic approaches
        5. Emerging markets growth
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Premenstrual Syndrome Treatment Market, By Drug Type,2021 - 2031 (USD Million)
      1. Analgesics
      2. Antidepressants
      3. Oral Contraceptives & Ovarian Suppression Agents
      4. Others
    2. Global Premenstrual Syndrome Treatment Market, By Type, 2021 - 2031 (USD Million)
      1. Prescription
      2. OTC
    3. Global Premenstrual Syndrome Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospitals Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
    4. Global Premenstrual Syndrome Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
      5. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
  6. Competitive Landscape
    1. Company Profiles
      1. ABBVIE INC
      2. AstraZeneca plc
      3. BASF Corporation
      4. Bayer AG.
      5. Dr. Reddys Laboratories Ltd
      6. Eli Lilly And Company.
      7. GlaxoSmithKline Plc.
      8. H. Lundbeck A/S
      9. Pfizer Inc.
      10. Shionogi Inc
  7. Analyst Views
  8. Future Outlook of the Market